中药治疗儿童与青少年难治性肺炎支原体肺炎的系统评价与Meta分析
该系统评价与Meta分析纳入17项试验共1451例儿童与青少年难治性肺炎支原体肺炎患者,评估中药联合治疗的效果与安全性。汇总结果显示中药可提高临床有效率并缩短退热、咳嗽消失、肺部啰音消失及肺部X线浸润消失时间,降低TNF-α水平,但不良事件两组无统计学差异;因纳入研究质量与数量限制,尚不能确认中药疗效。
要点
- 中药联合治疗可提高难治性肺炎支原体肺炎患儿临床有效率。
- 中药可缩短退热、咳嗽消失、肺部啰音消失及X线浸润消失时间。
- 不良事件两组无统计学差异,但证据质量有限需更多高质量RCT。
核心结论
- 中药在缓解临床症状、体征及降低炎症方面显示积极结果,但因纳入研究质量与数量限制,尚不能确认其治疗难治性肺炎支原体肺炎的疗效。
研究设计与样本
- 系统评价与Meta分析,检索7个数据库至2020年11月11日,纳入17项试验共1451例儿童与青少年难治性肺炎支原体肺炎患者。
主要发现
- 临床有效率RR=1.20,95%CI(1.15,1.25),p<0.00001。
- 退热时间MD=-2.60,95%CI(-3.06,-2.13),p<0.00001;咳嗽消失时间MD=-2.77,95%CI(-3.12,-2.42),p<0.00001。
- 肺部啰音消失时间MD=-2.65,95%CI(-3.15,-2.15),p<0.00001;肺部X线浸润消失时间MD=-2.75,95%CI(-3.33,-2.17),p<0.00001。
- TNF-α水平MD=-5.49,95%CI(-7.21,-3.77),p<0.00001;不良事件RR=0.97,95%CI(0.60,1.57),p=0.91。
- 亚组结果提示清热解毒化痰疗法在缩短退热时间、咳嗽消失时间、肺部X线浸润消失时间及降低TNF-α水平方面更具优势,活血化瘀疗法在缓解肺部啰音方面似乎更好。
临床怎么用
- 在临床中可考虑将中药作为难治性肺炎支原体肺炎患儿的联合治疗以改善症状与体征,但需结合研究质量局限谨慎决策。
局限性
- 纳入研究的质量与数量有限,尚需更多大规模、双盲、设计良好的随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: Chinese herb medicine (CHM) is one of the most popular complementary and alternative therapies, which has been widely used to treat Refractory Mycoplasma Pneumoniae Pneumonia (RMPP). However, the effect and safety of CHM remain controversial. Hence, we conducted this meta-analysis to evaluate whether CHM combination therapy could bring benefits to children and adolescents with RMPP. Methods: Seven databases were used for data searching through November 11, 2020 following the PRISMA checklist generally. Review Manager 5.3, Trial sequential analysis 0.9.5.10 Beta software and Stata16.0 were applied to perform data analyses. Mean difference or risk ratio was adopted to express the results, where a 95% confidence interval (CI) was applied. Results: In general, this research enrolled 17 trials with 1,451 participants. The overall pooled results indicated that CHM was beneficial for children and adolescents with RMPP by improving the clinical efficacy rate [RR = 1.20, 95% CI (1.15, 1.25), p < 0.00001], shortening antipyretic time [MD = -2.60, 95% CI (-3.06, -2.13), p < 0.00001], cough disappearance time [MD = -2.77, 95% CI (-3.12, -2.42), p < 0.00001], lung rale disappearance time [MD = -2.65, 95% CI (-3.15, -2.15), p < 0.00001], lung X-ray infiltrates disappearance time [MD = -2.75, 95% CI (-3.33, -2.17), p < 0.00001], reducing TNF-α level [MD = -5.49, 95% CI (-7.21, -3.77), p < 0.00001]. Moreover, subgroup results suggested that removing heat-phlegm and toxicity therapy had more advantages in shortening antipyretic time, cough disappearance time, lung X-ray infiltrates disappearance time and reducing TNF-α level. Meanwhile promoting blood circulation therapy seemed to be better at relieving lung rale. However, regarding adverse events, the two groups displayed no statistical difference [RR = 0.97, 95% CI (0.60, 1.57), p = 0.91]. Conclusion: Despite of the apparently positive results in relieving clinical symptoms, physical signs and reducing inflammation, it is premature to confirm the efficacy of CHM in treating RMPP because of the limitation of quality and the number of the included studies. More large-scale, double-blind, well-designed, randomized controlled trials are needed in future research.
引用
- Ling X, Sun X, Kong H, et al. Chinese Herbal Medicine for the Treatment of Children and Adolescents With Refractory Mycoplasma Pneumoniae Pneumonia: A Systematic Review and a Meta-Analysis. Front Pharmacol. 2021. PMID: 34177587. doi:10.3389/fphar.2021.678631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。